Prof. Dr. İrfan Çiçin

Association between beta-catenin (CTNNB1) mutations and clinical outcomes of pembrolizumab in advanced hepatocellular carcinoma (aHCC): Exploratory analyses from KEYNOTE-240.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.4109 3 Zitationen (OpenAlex) Quelle: OpenAlex

Perceptions and expectations: A study on prognostic perception and quality of life in patients with metastatic renal and bladder cancer.

Journal of Clinical Oncology, 2024

DOI 10.1200/jco.2024.42.16_suppl.e16505 Quelle: OpenAlex

GENERAL PRINCIPLES OF IMMUNOTHERAPY FOR SOLID TUMORS

Turkiye Klinikleri eBooks, 2024

DOI 10.5336/978-625-395-244-0_p1 Frei zugänglicher VolltextQuelle: OpenAlex

Prognostic factors for regorafenib treatment in patients with refractory metastatic colorectal cancer: A real-life retrospective multi-center study

Biomolecules and Biomedicine, 2023

DOI 10.17305/bb.2023.9253 PMID 37289436 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

BMC Cancer, 2023

DOI 10.1186/s12885-023-10609-8 PMID 36765293 18 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Major and minor salivary gland cancers: A multicenter retrospective study

Head & Neck, 2023

DOI 10.1002/hed.27376 PMID 37084179 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?

Journal of Cancer Research and Clinical Oncology, 2023

DOI 10.1007/s00432-023-05190-3 PMID 37480524 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Lazertinib Versus Gefitinib as First-Line Treatment in Patients With EGFR-Mutated Advanced Non–Small-Cell Lung Cancer: Results From LASER301

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.23.00515 PMID 37379502 131 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

The Lancet Oncology, 2023

DOI 10.1016/s1470-2045(23)00329-7 PMID 37591293 96 Zitationen (Europe PMC) Quelle: OpenAlex

Bintrafusp Alfa Versus Pembrolizumab in Patients With Treatment-Naive, Programmed Death-Ligand 1–High Advanced NSCLC: A Randomized, Open-Label, Phase 3 Trial

Journal of Thoracic Oncology, 2023

DOI 10.1016/j.jtho.2023.08.018 PMID 37597750 85 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Cancer-related hypercalcemia and potential treatments

Frontiers in Endocrinology, 2023

DOI 10.3389/fendo.2023.1039490 PMID 37033238 39 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Central Nervous System Outcomes of Lazertinib Versus Gefitinib in EGFR-Mutated Advanced NSCLC: A LASER301 Subset Analysis

Journal of Thoracic Oncology, 2023

DOI 10.1016/j.jtho.2023.08.017 PMID 37865896 29 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

Therapeutic Advances in Medical Oncology, 2023

DOI 10.1177/17588359231151840 PMID 36756142 16 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Molecular Pattern and Clinical Implications of KRAS/NRAS and BRAF Mutations in Colorectal Cancer

Current Issues in Molecular Biology, 2023

DOI 10.3390/cimb45100491 PMID 37886935 8 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Classifying invasive lobular carcinoma as special type breast cancer may be reducing its treatment success: A comparison of survival among invasive lobular carcinoma, invasive ductal carcinoma, and no-lobular special type breast cancer

PLoS ONE, 2023

DOI 10.1371/journal.pone.0283445 PMID 37428725 6 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

PNI as a Potential Add-On Biomarker to Improve the IMDC Intermediate Prognostic Score

Journal of Clinical Medicine, 2023

DOI 10.3390/jcm12196420 PMID 37835062 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Impact of adding pertuzumab to trastuzumab plus chemotherapy in neoadjuvant treatment of HER2 positive breast cancer patients: a multicenter real-life HER2PATH study

Acta Oncologica, 2023

DOI 10.1080/0284186x.2023.2202330 PMID 37083566 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Coexistence of Anti-PD1-Induced Immune Myocarditis and Complete Atrioventricular Block: A Case Report

The American Journal of Cardiology, 2023

DOI 10.1016/j.amjcard.2023.08.058 PMID 37722199 3 Zitationen (Europe PMC) Quelle: OpenAlex

Efficacy and safety of the proposed bevacizumab biosimilar BAT1706 compared with reference bevacizumab in patients with advanced nonsquamous non‐small cell lung cancer: A randomized, double‐blind, phase III study

Cancer Medicine, 2023

DOI 10.1002/cam4.6664 PMID 37935428 5 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Genetic testing and counseling challenges in personalized breast cancer care: review article with insights from Türkiye

Future Oncology, 2023

DOI 10.2217/fon-2023-0518 PMID 38014519 Frei zugänglicher VolltextQuelle: OpenAlex

Is the “ P -value” Alone a Sufficient Metric for the Magnitude of Clinical Benefit and Which Clinical Trial Is Actually Positive, KEYNOTE-394 or KEYNOTE-240?

The Oncologist, 2023

DOI 10.1093/oncolo/oyad145 PMID 37294662 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

An experimental study: the effect of S. boulardii on abemaciclib-induced diarrhea

TURKISH JOURNAL OF MEDICAL SCIENCES, 2023

DOI 10.55730/1300-0144.5557 PMID 36945921 Frei zugänglicher VolltextQuelle: OpenAlex

Erdafitinib (ERDA) vs ERDA plus cetrelimab (ERDA+CET) for patients (pts) with metastatic urothelial carcinoma (mUC) and fibroblast growth factor receptor alterations (FGFRa): Final results from the phase 2 Norse study.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.4504 47 Zitationen (OpenAlex) Quelle: OpenAlex

Abstract GS1-09: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Cancer Research, 2023

DOI 10.1158/1538-7445.sabcs22-gs1-09 3 Zitationen (OpenAlex) Quelle: OpenAlex

Circulating tumor DNA (ctDNA) dynamics and survival outcomes in patients (pts) with advanced non-small cell lung cancer (aNSCLC) and high (>50%) programmed cell death-ligand 1 (PD-L1) expression, randomized to cemiplimab (cemi) vs chemotherapy (chemo).

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.9022 3 Zitationen (OpenAlex) Quelle: OpenAlex

Awareness and perceptions of clinical trials in patients with cancer and their families in Turkey.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.e18780 1 Zitation (OpenAlex) Quelle: OpenAlex

Patient preferences for use of archived biospecimens in Turkey.

Journal of Clinical Oncology, 2023

DOI 10.1200/jco.2023.41.16_suppl.e18904 Frei zugänglicher VolltextQuelle: OpenAlex

Clinical and Radiological Features and Treatment of Pulmonary Toxicity Associated with Using Immune Checkpoint Inhibitors in Cancer Treatment: A Single-Center Experience

Journal of Oncological Sciences, 2023

DOI 10.37047/jos.2023-95972 Frei zugänglicher VolltextQuelle: OpenAlex

Comparison of Extrapulmonary Small Cell Carcinoma and Small Cell Lung Carcinoma: A Single-Center Study

Journal of Oncological Sciences, 2023

DOI 10.37047/jos.2023-97197 Frei zugänglicher VolltextQuelle: OpenAlex

O10-2 Telisotuzumab vedotin monotherapy in Asian patients with c-Met–overexpressing advanced non-small cell lung cancer

Annals of Oncology, 2023

DOI 10.1016/j.annonc.2023.09.134 Frei zugänglicher VolltextQuelle: OpenAlex

Real-world treatment outcomes from nationwide Onco-colon Turkey registry in RAS wild-type patients treated with biologics second-line mCRC.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.e15562 Quelle: OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.e12610 2 Zitationen (OpenAlex) Quelle: OpenAlex

The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

Medicine, 2022

DOI 10.1097/md.0000000000030147 PMID 36107512 3 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

The Lancet Oncology, 2022

DOI 10.1016/s1470-2045(22)00694-5 PMID 36493792 534 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

JAMA, 2022

DOI 10.1001/jama.2022.16464 PMID 36166026 454 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

Cancer, 2022

DOI 10.1002/cncr.34477 PMID 36308296 18 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Real-world Treatment Sequencing in Patients with Metastatic Castration-resistant Prostate Cancer: Results from the Prospective, International, Observational Prostate Cancer Registry

European Urology Open Science, 2022

DOI 10.1016/j.euros.2022.08.018 PMID 36353661 13 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

ALK TKI therapy in patients with ALK-positive non-small cell lung cancer and brain metastases: A review of the literature and local experiences

Critical Reviews in Oncology/Hematology, 2022

DOI 10.1016/j.critrevonc.2022.103847 PMID 36257531 9 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Efficacy and safety of trifluridine/tipiracil in older and younger patients with metastatic gastric or gastroesophageal junction cancer: subgroup analysis of a randomized phase 3 study (TAGS)

Gastric Cancer, 2022

DOI 10.1007/s10120-021-01271-9 PMID 34997449 10 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Breast Cancer Targets and Therapy, 2022

DOI 10.2147/bctt.s380754 PMID 36105268 12 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database

Clinical Genitourinary Cancer, 2022

DOI 10.1016/j.clgc.2022.07.006 PMID 35970759 6 Zitationen (Europe PMC) Quelle: OpenAlex

Relationship between prognostic nutritional index and neutrophil lymphocyte ratio with overall survival in patients with metastatic colorectal cancer receiving regorafenib

Journal of Cancer Research and Therapeutics, 2022

DOI 10.4103/jcrt.jcrt_1620_21 PMID 37470607 4 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Recurrent Delayed Immune-Related Pneumonitis After Immune-Checkpoint Inhibitor Therapy for Advanced Osteosarcoma

Immunotherapy, 2022

DOI 10.2217/imt-2021-0275 PMID 35152716 7 Zitationen (Europe PMC) Quelle: OpenAlex

Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: PRECONNECT Turkey

Future Oncology, 2022

DOI 10.2217/fon-2022-0455 PMID 36040321 2 Zitationen (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

Cancers, 2022

DOI 10.3390/cancers14051168 PMID 35267477 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: OpenAlex

Telisotuzumab vedotin (Teliso-V) monotherapy in patients (pts) with previously treated c-Met–overexpressing (OE) advanced non-small cell lung cancer (NSCLC).

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9016 70 Zitationen (OpenAlex) Quelle: OpenAlex

Clinical efficacy and safety of the BAT1706 (proposed bevacizumab biosimilar) compared with reference bevacizumab in patients with advanced nonsquamous NSCLC: A randomized, double-blind, phase III study.

Journal of Clinical Oncology, 2022

DOI 10.1200/jco.2022.40.16_suppl.9041 3 Zitationen (OpenAlex) Quelle: OpenAlex

Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series

Research Square, 2022

DOI 10.21203/rs.3.rs-1447957/v1 Frei zugänglicher VolltextQuelle: OpenAlex

Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series

2022

DOI 10.32388/ub8v1e Frei zugänglicher VolltextQuelle: OpenAlex

Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study).

Bursa Uludag University - AVESIS, 2022

Quelle: OpenAlex